Half Year 2026 HUTCHMED (China) Ltd Earnings Call Transcript

Jul 30, 2026 / 12:00 PM GMT

Release Date Price: €1.87 (-2.09%)

Transcript

Key Points

Positve

Strong China product sales growth, with Elunate and Zolenta growing over 40%.
Fruquintinib global in-market sales grew 70% in ex-US markets due to rapid geographic expansion.
Two new drug approvals received: fruquintinib for RCC and savolitinib for GC.
Novel ATTC platform advancing with two first-in-class assets in Phase 1 trials and a third cleared for IND.
Company remains profitable with net income of $60 million and a strong cash reserve of $1.4 billion.

Negative

R&D expenses increased to $79 million from $72 million due to investments in ATTC trials and discovery capabilities.
Other ventures revenue declined by nearly 20% due to expanded volume-based procurement in China.
Full-year guidance range of $330 million to $450 million is wide, with lower end dependent on no business development contributions.
No additional milestones expected from partners in the second half beyond a sales milestone for fruquintinib.
ATTC clinical data readouts not expected until 2027, leaving near-term pipeline catalysts limited.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

0013.HK - HUTCHMED (China) Ltd
Half Year 2026 HUTCHMED (China) Ltd Earnings Call
Jul 30, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome everyone.

Thank you for joining HutchMed 2026 interim results announcement and presentation.

Before we start, I would just like to go over the safe harbour statement and disclaimer on page 2. The performance and results of operation of HutchMed Group contained within this presentation are historical in nature and past performance is no guarantee of future results.

Next, I would like to invite our acting CEO and CFO Johnny Chen to start the opening. Johnny.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Okay, thank you, David. And I

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.